---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-24-000055"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:47:30.533755+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharmaceuticals announces FDA partial clinical hold on seclidemstat trial after grade 4 adverse event

## Summary
- A patient in MDACC's trial of seclidemstat + azacitidine for MDS/CMML experienced a serious unexpected grade 4 adverse event.
- FDA placed partial clinical hold; no new patients may enroll, but current subjects benefiting may continue treatment.
- Salarius will support MDACC in analyzing data and responding to FDA questions.

## SEC filing metadata
- accession: 0001615219-24-000055
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000055/0001615219-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000055/flks-20240709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-24-000055
- JSON: https://secwatch.observer/filing/0001615219-24-000055.json
- Plain text: https://secwatch.observer/filing/0001615219-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.